Does Flexeril Show Up on a 10-Panel Drug Test?

Quick answer: No. Flexeril (cyclobenzaprine) is not a target analyte on a standard 10-panel urine drug test. Because its structure resembles tricyclic antidepressants, it can trigger a false-positive on a TCA assay if the panel includes one, typically at a 1,000 ng/mL cutoff. Confirm any presumptive positive with lab GC-MS or LC-MS/MS.

• Standard 10-panel cups do not look for cyclobenzaprine, so a prescribed dose will not normally cause a positive.
• Panels that swap in a TCA channel are the main exception, since cyclobenzaprine can cross-react.
• Every non-negative immunoassay result is presumptive until a laboratory confirms it.

What a 10-panel test detects

Flexeril is a prescription muscle relaxant. Its generic name is cyclobenzaprine. A 10-panel urine test is an immunoassay screen, and it only flags the drug classes it is built to detect. Cyclobenzaprine is not one of them.

The 10-panel configuration is not fixed. Most include the following, though exact cutoffs vary by manufacturer and product:

• Amphetamines (AMP), commonly 500 or 1,000 ng/mL
• Barbiturates (BAR), commonly 300 ng/mL
• Benzodiazepines (BZO), commonly 300 ng/mL
• Cocaine metabolite (COC), 300 ng/mL
• Methamphetamine (MET), commonly 500 or 1,000 ng/mL
• Methadone (MTD), 300 ng/mL
• Opiates (OPI), commonly 2,000 ng/mL (some use 300)
• Phencyclidine (PCP), 25 ng/mL
• Marijuana metabolite (THC), 50 ng/mL
• A tenth channel that varies, such as propoxyphene, MDMA, oxycodone or tricyclic antidepressants

That last slot is where Flexeril matters. Always read the product insert for the exact analytes and cutoffs of the device you buy.

Why cyclobenzaprine can still cause a problem

According to the MedlinePlus drug information page for cyclobenzaprine, the drug is a skeletal muscle relaxant. Its chemical structure is closely related to tricyclic antidepressants such as amitriptyline. TCA immunoassays use antibodies that recognize that shared tricyclic ring structure, so cyclobenzaprine and its metabolites can cross-react and produce a presumptive TCA positive.

There are also occasional published reports of cyclobenzaprine interfering with other immunoassays. Cross-reactivity differs by manufacturer and antibody, so do not assume a result is real or false from the drug name alone. The only reliable way to settle it is confirmatory testing.

Decision table: which panel, what to expect

Regulated testing: SAMHSA and DOT

Federal workplace testing is narrower than a 10-panel. The SAMHSA workplace drug testing program sets the Mandatory Guidelines used for federal agencies and DOT-regulated employers. The DOT panel covers marijuana, cocaine, amphetamines, opioids and PCP. Cyclobenzaprine is not on it. DOT-regulated tests also go through a Medical Review Officer, who can verify legitimate prescriptions. For details, see the DOT Office of Drug and Alcohol Policy and Compliance (ODAPC) pages.

Non-regulated employers, courts, treatment programs and probation offices have more latitude, but the same principle holds. A presumptive result needs context and confirmation before anyone acts on it.

How to read and handle a result

1. Check the device insert to confirm which analytes and cutoffs (ng/mL) the cup or card uses.
2. Read the result within the window stated in the instructions. Do not interpret lines after the time limit.
3. Treat any line indicating a non-negative as presumptive, not final.
4. Ask the donor about prescription and over-the-counter medications, and document the answer.
5. Send the specimen to a laboratory for confirmation by GC-MS or LC-MS/MS.
6. Route the confirmed result to a medical reviewer when a legitimate prescription is claimed.

Checklist for clinics, employers and courts

• Verify the exact panel configuration before purchase, especially whether a TCA channel is included.
• Confirm the FDA clearance and CLIA-waiver status stated on the product documentation for each device.
• Collect a medication disclosure form at the time of the test.
• Write a policy stating that no adverse action follows a presumptive result alone.
• Keep a lab confirmation pathway and chain-of-custody forms ready.
• Train staff to read results inside the labeled time window.
• Retain the specimen for the period your policy or jurisdiction requires.

Choosing the right device

If your program does not need to screen for tricyclics, pick a panel without a TCA channel to avoid ambiguity from muscle-relaxant prescriptions. If your population includes patients on antidepressants, a TCA channel may be valuable, and you should plan for confirmation. You can compare configurations in our drug test cups collection. If you are unsure which panel fits your protocol, contact American Screening Corp and our team will help you match a product to your testing policy.

Frequently asked questions

Does Flexeril show up on a standard 10-panel drug test?

No. Cyclobenzaprine is not a target of the standard 10-panel drug classes. A prescribed dose should not cause a positive on a panel without a TCA channel.

Can Flexeril cause a false positive for tricyclic antidepressants?

Yes, it can. Cyclobenzaprine is structurally similar to tricyclics, so a TCA immunoassay (commonly 1,000 ng/mL cutoff) may read presumptive positive. Lab confirmation distinguishes the compounds.

Does Flexeril appear on a DOT drug test?

No. The DOT panel tests for marijuana, cocaine, amphetamines, opioids and PCP. A Medical Review Officer evaluates any verified non-negative result alongside prescription information.

How should we confirm a questionable result?

Send the specimen to a laboratory for GC-MS or LC-MS/MS confirmation, document the donor's medications and have a medical reviewer interpret the result before any decision.

Sources

• MedlinePlus (NIH): Cyclobenzaprine
• SAMHSA: Workplace Drug Testing
• U.S. DOT: Office of Drug and Alcohol Policy and Compliance

This article is general information, not legal or medical advice.